Human IP-10 Recombinant

Catalog #
90203-B
$205 *
Size: 25 µg
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Recombinant human IP-10 (also known as CXCL10) is a disulfide-linked homodimeric protein consisting of 78 amino acid residues, and migrates as an approximately 9 kDa protein under non-reducing and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human IP-10 mature chain was expressed in E. coli.

Synonyms
IP-10, CXCL10, IFN-gamma-inducible protein-10, IP10
Product Info
Storage and Usage
Citations
Species
Human
Host Species/Expression System
E. coli
Purity
≥97% by SDS-PAGE and HPLC
Format
lyophilized protein
Formulation
Lyophilized from a 0.2 µm filtered PBS solution, pH 7.0
MW
9 kDa
Endotoxin Level
<0.1 ng/µg (1 EU/µg), using the LAL gel clot method.
Amino Acids
22–98
Biological Activity
Determined by its ability to chemoattract human T-Lymphocytes using a concentration of 10-50 ng/ml.
Genbank #
P02778
UniProt #
P02778
Background
IP10 shows homology to PF4 (platelet factor-4) and belongs to the family of chemotactic cytokines known as Chemokines. The receptor for IP-10 is CXCR3. IP-10 has been shown to bind to the virus-encoded viroceptor M3. The expression of IP-10 from a variety of cells, including monocytes, endothelial cells, keratinocytes, and fibroblasts, is induced by IFN-gamma and TNF-alpha. Human neutrophils produce IP-10 in response to IFN- gamma in combination with either TNF-alpha or bacterial lipopolysaccharides. IP-10 probably also plays a role in regulation of the growth of immature hematopoietic progenitor cells. It has been shown to suppress in vitro colony formation of highly enriched cells expressing the cell surface marker CD34 in the presence of SCF, GM-CSF, or SCF and EPO, but not in their absence with the exception of SCF.

Native human IP-10/CXCL10, generated by the proteolytic removal of the signal peptide and propeptide, the molecule has a calculated molecular mass of approximately 9 kDa.
References
1. Invest. Ophthalmol. Vis. Sci., Apr 2008, 49: 3721.
2. J. Biol. Chem., Jan 2001, 276: 2986 - 2991.